Views & Analysis | Perspectives on pharma industry issues

Patients

pharmaphorum podcast Episode 244, Jeff Harper - IntelliGuard

On addressing drug waste and ensuring access, with Jeff Harp...

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

R&D

AMR and vaccines: Can universal coverage avert a post-antibi...

Antimicrobial resistance (AMR) is a growing global health crisis.

Patients

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

R&D

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

Prive Bio CEO Laurent Audaly spoke with pharmaphorum during the JP Morgan Healthcare conference, discussing GLP-1s in the cardiometabolic space.

R&D

Changing Faces: Pharma and biotech, January 2026

The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO changes at biotech firms.

Market Access

Sustaining the mature product portfolio through strategic ou...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

Oncology

Medically accurate representation of a cancer cell

Radiopharmaceutical innovation: Giving cancer drugs second c...

Molecular recycling could transform the economics and innovation of oncology drug discovery.

R&D

pharmaphorum podcast Episode 225, Simon Kohl, Latent Labs

Towards a democratic era of medicine, with Simon Kohl

In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.

Sales & Marketing

Four reasons pharma is sweeping the Super Bowl despite FDA f...

The FDA has signalled increased scrutiny of D2C pharma advertising. So why is pharma stepping up its advertising at Super Bowl LX?

Sales & Marketing

pharmaphorum podcast Episode 243, Lisa Sims, Novartis

On quality data for quality learnings, with Lisa Sims

Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, about personalising learning at scale.

Digital

From engagement metrics to meaningful experience: Why pharma...

Pharma digital success still focuses on clicks and downloads, but true performance is whether content actually meets real end-user needs

Digital

Activation of the G protein-coupled GABA B receptor by the agonist baclofen

How GenAI is cracking the toughest targets in drug discovery

Generative AI has the potential to solve for designing effective antibodies for G‑protein coupled receptors (GPCRs).

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

A cancer treatment modality that prioritises QoL, with Ben Z...

Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.

Oncology

Improving breast cancer outcomes in sub-Saharan Africa

New funding from The Pfizer Foundation will support breast cancer efforts in Kenya by the Academic Model Providing Access to Healthcare (AMPATH).

Oncology

Engineering “smarter” cells, with Tim Lu

Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone

Patients

On addressing drug waste and ensuring access, with Jeff Harp...

The rising cost of drugs in 2025 was driven by several factors, including inflation, supply chain issues, and the demand for specialty drugs.

Patients

From insight to impact: Why the patient voice will redefine ...

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

Patients

Pills from bottle without label into palm of a man's hand

Meeting the growing demand for animal-free medicines

Pharmaceutical manufacturers have begun, albeit tentatively, to acknowledge and respond to evolving dietary sensibilities.

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks